Aditxt Inc (ADTX) Actualités

Form 8-K - Current report

Form 8-K - Current report

Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations...

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025

Received overwhelming shareholder support in favour of take-private transaction with Aditxt Advanced key...

Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time

Co-founder and CEO Amro Albanna to Provide a Company Update Followed by Q&A Session Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX...

Form DEF 14A - Other definitive proxy statements

Form PRER14A - Preliminary Proxy Soliciting materials

Form 8-K - Current report

Aditxt’s Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, is...

Form 8-K - Current report

Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials

Submission for Regulatory Approval to Initiate Human Trials for Type 1 Diabetes, Psoriasis, and Stiff-Person Syndrome Targeted for H2 2025...

Form PRE 14A - Other preliminary proxy statements

Form 8-K/A - Current report: [Amend]

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report